HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9, indicating confidence in the company's future performance.
October 23, 2024 | 9:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Alpha Tau Medical and maintained a $9 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. indicates a positive outlook for Alpha Tau Medical. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100